Botox Spasticity denied as experimental or investigational by Humana?

Humana's specific coverage criteria for botox spasticity are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny OnabotulinumtoxinA (Botox) for Spasticity as "Experimental" — and Why That Denial Is Highly Appealable

OnabotulinumtoxinA (Botox) carries FDA approval specifically for spasticity in adult upper and lower limbs, making an "experimental or investigational" denial for this indication highly vulnerable on appeal. These denials typically arise in one of two scenarios: (1) the ICD-10 diagnosis code submitted does not clearly map to an FDA-approved spasticity indication covered under Humana's policy, or (2) the claim involved an off-label muscle group or pediatric use that Humana's policy does not expressly list as covered, leading the system to classify it under experimental criteria.

Regardless of the trigger, an appeal grounded in the FDA approval status and the applicable clinical guideline endorsement from organizations such as the American Academy of Neurology or the American Academy of Physical Medicine and Rehabilitation is a strong basis for reversal.

## Federal Appeal Framework

ACA §2719 requires non-grandfathered plans to offer internal appeal and, if denied, independent external review by an accredited IRO. ERISA §503 provides full-and-fair review rights for self-funded plans. You have approximately four months from the final internal denial to request external review. Request expedited review if functional impairment is worsening rapidly — the IRO must respond within 72 hours.

## Concrete Appeal Steps and Timeline

1. Obtain the denial letter, denial reason code, and Humana's published experimental/investigational policy for botulinum toxin. 2. Confirm the exact indication and diagnosis codes submitted; correct any coding mismatch before or alongside the appeal. 3. File the Level 1 internal appeal by the deadline printed on the denial notice. 4. If Level 1 fails, escalate to Level 2 or IRO external review. 5. Note that under many state external review statutes, an IRO finding in your favor is binding on Humana.

## Documentation to Gather

• Diagnosis confirmation: chart documentation of the underlying neurological condition causing spasticity and the specific muscle groups affected
• FDA approval reference: the current FDA-approved prescribing information (label) for Botox confirming the spasticity indication — obtain directly from Allergan/AbbVie or FDA.gov
• Prior treatment history: documentation of oral antispasticity agents, physical and occupational therapy trials, and outcomes
• Clinical severity: functional and spasticity assessments recorded in the chart
• Guideline endorsement: a statement from the prescriber referencing the relevant professional society guideline organization (without citing specific numbers)
• Prescriber medical-necessity letter affirming FDA-approved use and addressing Humana's experimental criteria point by point

## Criteria-Mapping Structure

Pull Humana's experimental/investigational coverage policy criteria and address each:

| Humana Experimental Criteria | Your Response | |---|---| | Is the treatment FDA-approved for this indication? | [Cite FDA label — Botox adult upper/lower limb spasticity] | | Is the indication supported by professional society guidelines? | [Reference AAN or AAPM&R guideline organization] | | Is the treatment recognized as standard of care? | [Prescriber attestation + peer-reviewed support without specific statistics] | | Diagnosis code alignment with covered indication | [Confirm correct ICD-10 mapping] |

A clear, organized response to each experimental criterion — paired with the FDA label and a strong prescriber letter — makes this one of the more straightforward denial categories to reverse.